Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Dyslipidemia

Dyslipidemia

16 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Dyslipidemia

72 trials tracked for Dyslipidemia: 33 in phase 3 or 4 and 7 with published results. The most-cited published study has 481 citations.

72Trials tracked
33Phase 3 & 4
0Recruiting
7With published results
Phase distribution
Phase 4 7 Phase 3 26 Phase 2 15 Phase 1 6 Other / NA 18
  1. Phase 3 Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects Completed · 481 cited
  2. Phase 3 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension Completed · 378 cited
  3. Phase 3 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Completed · 169 cited
  4. Phase 4 Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia) Completed · 126 cited
  5. Phase 4 Effects of Metformin on Hepatic FFA Metabolism Completed · 63 cited
  6. Phase 4 Effects of Pitavastatin on Lipid Profiles in HIV-infected Patients With Dyslipidemia and Receiving Atazanavir/Ritonavir Completed · 11 cited
Show 44 more trials
  1. Phase 3 Efficacy/Safety of Rosuvastatin+Ezetimibe in High Risk Patients With Primary Hypercholesterolemia/Mixed Dyslipidemia Completed · 7 cited
  2. Phase 4 Omega-3 Fatty Acids for High Triglycerides in HIV-infected Patients Completed
  3. Phase 4 A 12-Week Study Comparing Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV-Infected Subjects Completed
  4. Phase 4 A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk Completed
  5. Phase 4 Effect of Plant Sterols Esterified to Fish Oil Fatty Acids on Plasma Lipid Levels Completed
  6. Phase 3 Fenofibrate Treatment in SCI Completed
  7. Phase 3 12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia Completed
  8. Phase 3 Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the Blood Completed
  9. Phase 3 A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia Completed
  10. Phase 3 Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors Completed
  11. Phase 3 Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood Completed
  12. Phase 3 Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia Completed
  13. Phase 3 Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia. Completed
  14. Phase 3 A 12-week Study to Compare the Efficacy and Safety of Fixed Combinations of Fenofibrate/Simvastatin 145/20mg and Fenofibrate/Simvastatin 145/40mg Tablets Versus Fenofibrate or Simvastatin Monotherapies in Subjects With Abnormal Blood Levels of Fats (Lipids) and at High Risk of Cardiovascular Disease Completed
  15. Phase 3 Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin Completed
  16. Phase 3 30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease Completed
  17. Phase 3 Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin Completed
  18. Phase 3 A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia Completed
  19. Phase 3 Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels Completed
  20. Phase 3 Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin Completed
  21. Phase 3 Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia Completed
  22. Phase 3 Multi-Targeted Cardiac Risk Intervention in Type 2 Diabetes Completed
  23. Phase 3 Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia Completed
  24. Phase 3 Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood Completed
  25. Phase 3 Long-Term Extension Study of Pitavastatin in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia Completed
  26. Phase 3 Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood Completed
  27. Phase 3 A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102) Completed
  28. Phase 2 Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study Completed
  29. Phase 2 ABT-335 (Choline Fenofibrate) Reverse Cholesterol Transport (RCT) Study Completed
  30. Phase 2 A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides Completed
  31. Phase 2 A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia Completed
  32. Phase 2 A Study of AZD8233 in Participants With Dyslipidemia. Completed
  33. Phase 2 Preliminary Study of Safety and Efficacy of Policosanol Completed
  34. Phase 2 Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes Completed
  35. Phase 2 A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins Completed
  36. Phase 2 A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy. Completed
  37. Phase 2 A Study to Assess the Effect of RO4607381 in Patients With Relatively Low Levels of High Density Lipoprotein-Cholesterol (HDL-C) Completed
  38. Phase 2 A Study to Evaluate MK1903 in Patients With Dyslipidemia (MK1903-004) Completed
  39. Phase 2 A Study of LY2484595 in Patients With High LDL-C or Low HDL-C Completed
  40. Phase 2 A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins Completed
  41. Phase 2 Study to Investigate the Efficacy and Pharmacokinetic Profile of K-877-ER Compared to K-877-IR Completed
  42. Phase 2 Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia Completed
  43. Phase 1 Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia Completed
  44. Phase 1 MK0524B Bioequivalence Study (0524B-070) Completed

Showing the 50 most-cited and recently-updated of 72 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology
Cardiology Sys. Review
Multi-target therapies may address combined hypertension and dyslipidemia pathophysiology Multi-Target Therapies May Address Combined Hypertension and High Cholesterol
This systematic review synthesizes evidence on synergistic mechanisms of hypertension and dyslipidemia, highlighting the RAAS/PPAR axis, AMP…
Combining treatments like statins and RAAS inhibitors may offer a more precise way to manage both high blood pressure and cholesterol levels…
Frontiers Jun 11, 2026
Preoperative comorbidities linked to reduced weight loss after metabolic and bariatric surgery in adults
Nutrition & Obesity Medicine Meta-analysis
Preoperative comorbidities linked to reduced weight loss after metabolic and bariatric surgery in adults Pre-existing health conditions may slightly reduce weight loss after surgery
A meta-analysis of twenty-three studies reveals that mental illness, diabetes, and sleep apnea are associated with slightly lower weight los…
Adults with mental illness or diabetes before surgery saw slightly less weight loss. Other conditions like high blood pressure did not affec…
Jun 6, 2026
Expert consensus guideline on cholesterol-lowering strategies for Chinese population with dyslipidemia and ASCVD
Drug Pipeline Guideline
Expert consensus guideline on cholesterol-lowering strategies for Chinese population with dyslipidemia and ASCVD New guidelines offer cholesterol strategies for Chinese patients with heart disease
This is an expert consensus guideline for the Chinese population. It synthesizes initial cholesterol-lowering strategies to improve dyslipid…
Experts in China share updated advice to better prevent and manage high cholesterol and artery disease for local patients.
Frontiers May 24, 2026
Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients
Allergy & Immunology Sys. Review
Narrative review examines metabolic syndrome and novel agents in kidney transplant recipients Kidney transplant patients face high metabolic risks and rejection
This narrative review addresses antibody-mediated rejection and metabolic syndrome in kidney transplantation recipients. The authors note th…
About half of kidney transplant recipients develop metabolic problems within a year, while antibody-mediated rejection remains a major cause…
Frontiers May 21, 2026
FDA Approves Crestor (rosuvastatin) for Cardiovascular Risk Reduction in Adults
Cardiology FDA Approval
FDA Approves Crestor (rosuvastatin) for Cardiovascular Risk Reduction in Adults FDA approves Crestor to prevent heart attacks and strokes in certain adults.
FDA approved Crestor (rosuvastatin) to reduce risk of major adverse cardiovascular events in adults without established coronary heart disea…
The FDA approved Crestor (rosuvastatin) to reduce the risk of heart attack, stroke, and related events in adults without heart disease but w…
FDA May 5, 2026
Narrative review on dyslipidemia and erectile dysfunction pathophysiology
Diabetes & Endocrinology Sys. Review
Narrative review on dyslipidemia and erectile dysfunction pathophysiology High Cholesterol May Damage Sexual Function Directly
This narrative review synthesizes evidence on dyslipidemia and erectile dysfunction.
High blood fats may directly harm sexual function beyond just heart risks.
Frontiers Apr 23, 2026
Dyslipidemia linked to poorer renal survival in primary IgA nephropathy patients
Nephrology Cohort
Dyslipidemia linked to poorer renal survival in primary IgA nephropathy patients High cholesterol linked to faster kidney failure in IgA nephropathy
This retrospective observational cohort study of 458 primary IgA nephropathy patients found that dyslipidemia was associated with poorer ren…
People with IgA nephropathy and high cholesterol face a higher risk of kidney failure, a new study finds.
Frontiers Apr 23, 2026
Chronic Insomnia in Hospitalized Adults: Associated Conditions and Metabolic Abnormalities
Psychiatry Cohort
Chronic Insomnia in Hospitalized Adults: Associated Conditions and Metabolic Abnormalities Elderly women with insomnia often have heart disease, infections, and metabolic issues
This retrospective observational study evaluated 871 hospitalized adults aged 18 to 100 years with chronic insomnia at a single center in Ch…
Hospitalized older women with insomnia frequently face infections, heart disease, and blood sugar problems, a single-center study finds.
Frontiers Apr 22, 2026
Review of UK Biobank data identifies plasma protein mediators in cardiometabolic disease progression
Diabetes & Endocrinology
Review of UK Biobank data identifies plasma protein mediators in cardiometabolic disease progression New Blood Test Clues Could Predict Diabetes Complications Years Earlier
This observational review analyzes UK Biobank data from 53,030 participants to evaluate plasma proteins as mediators in secondary disease de…
A new blood test spots specific proteins that warn of heart, kidney, and brain problems years before they happen in people with diabetes or …
medRxiv Apr 19, 2026
Night shift work linked to elevated total cholesterol in male miners, cross-sectional analysis finds
Psychiatry Cohort
Night shift work linked to elevated total cholesterol in male miners, cross-sectional analysis finds Your Shift Work Raises Cholesterol Even If You Sleep Well
A cross-sectional analysis of 921 male underground miners in the Kailuan Group found night shift work (0:00–7:59) was associated with higher…
Night shift work raises cholesterol levels even when workers sleep well, proving that fixing your sleep isn't enough to protect your heart h…
Frontiers Apr 14, 2026
Meta-analysis finds HIIT and aerobic training improve different lipid parameters in youth with dyslipidemia
Pediatrics Meta-analysis
Meta-analysis finds HIIT and aerobic training improve different lipid parameters in youth with dyslipidemia Kids' Cholesterol: Sprinting or Jogging?
A systematic review and meta-analysis in children and adolescents with dyslipidemia found high-intensity interval training (HIIT) was superi…
High-intensity sprinting beats steady jogging for lowering bad cholesterol in kids, though doctors mix both moves to manage all heart health…
Apr 12, 2026
Plant bioactive polysaccharides show metabolic benefits in umbrella review of systematic reviews
Diabetes & Endocrinology Meta-analysis
Plant bioactive polysaccharides show metabolic benefits in umbrella review of systematic reviews Plant polysaccharides show potential benefits for blood sugar, cholesterol, and gut health
An umbrella review of systematic reviews and meta-analyses found plant bioactive polysaccharides had significant effects on blood lipids and…
Plant polysaccharides linked to better blood sugar, cholesterol, gut health, and weight control, though no effect on blood pressure or liver…
Apr 6, 2026

Questions about Dyslipidemia

Are there metabolic problems linked to having chronic insomnia while hospitalized?

Yes, chronic insomnia in hospitalized adults is linked to metabolic problems, including elevated fasting blood glucose and dyslipidemia.

Full answer →
What blood proteins might help predict disease progression in people with cardiometabolic conditions?

Proteins like GDF15, ADM, PCSK9, HS-CRP, and S100 proteins may help predict disease progression in people with cardiometabolic conditions.

Full answer →
Does working night shifts cause higher total cholesterol levels in male miners?

Yes, night shift work is linked to higher total cholesterol in male miners, even after accounting for sleep quality, age, and lifestyle factors.

Full answer →
Can high cholesterol levels make kidney disease worse for patients with IgA nephropathy?

Yes, high cholesterol levels can worsen kidney disease in IgA nephropathy patients, as dyslipidemia is linked to poorer renal survival and more severe kidney damage.

Full answer →

All Dyslipidemia Articles